CITIUS ONCOLOGY, INC.

Citius Oncology, Inc. (Nasdaq: TENK) is a commercial-stage biopharmaceutical company focused on oncology therapeutics that emerged from the business combination of TenX Keane Acquisition Corp., a blank-check company sponsored by TenX Capital Management, which completed its initial public offering in 2021. The de-SPAC transaction closed in 2023, with the combined entity retaining the TENK ticker on Nasdaq. Citius Oncology's principal commercial asset is LYMPHIR (denileukin diftitox), an FDA-approved agent for relapsed or refractory CD25-positive cutaneous T-cell lymphoma. The company filed an 8-K with the Securities and Exchange Commission on August 12, 2026. For full filing history, deal analytics, and real-time updates on Citius Oncology and the broader SPAC universe, sign up for a free SpacDesk account at spacdesk.com.